+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 70Years
All Genders
ID07358195

Evaluating Venetoclax Addition to Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation in Patients With Chronic Kidney Disease and Blood Cancers

Led by Massachusetts General Hospital · Updated on 2026-10-14

3

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety of adding venetoclax to a reduced intensity conditioning regimen for patients undergoing combined hematopoietic stem cell and kidney transplantation. It focuses on people with chronic kidney disease and blood cancers who have a suitable donor match. The main goal is to observe stable donor blood cell presence and avoid severe toxicity caused by venetoclax during the treatment. Participants receive venetoclax orally once daily from 8 days before to 1 day before transplantation, along with chemotherapy and radiation conditioning. This is followed by a living donor kidney transplant and infusion of donor stem cells from bone marrow or peripheral blood. Venetoclax dosing will be monitored carefully to prevent tumor lysis syndrome, and the conditioning includes cyclophosphamide, fludarabine, and total body irradiation. Throughout the study, participants are closely monitored for donor blood cell stability, severe toxicities related to venetoclax, kidney transplant rejection, graft-versus-host disease, and overall survival up to 24 months after transplantation. Safety assessments and laboratory tests guide treatment, and participants must use reliable birth control during and for 1 year after treatment. The study lasts until the final outcome measurements at 24 months post-transplantation.

CONDITIONS

Brief Title

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Research Team

T

Thomas Spitzer, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here